Focal therapy using ST-4PC, an injectable, polymeric paste containing docetaxel (dtx) and bicalutamide (bic), has shown promise for focal therapy of prostate cancer. The in vitro characteristics of ST-4PC were tested using high-performance liquid chromatography to assess drug release and rodent models used to evaluate in vivo toxicity and efficacy. Sustained and steady release of the drugs was observed with no systemic toxicity. In a subcutaneous tumour model, 0.1%/4% and 0.25%/4% dtx/bic ST-4PC paste significantly reduced PSA progression but did not significantly reduce tumour volume, whereas in the orthotopic xenograft model ST-4PC loaded with 1%/4% dtx/bic significantly reduced tumour volume, serum PSA and bioluminescence. Further investigation of ST-4PC is warranted.
References
Original article
Kesch, C. et al. A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-019-0190-x (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fenner, A. A polymeric paste for intratumoural therapy. Nat Rev Urol 17, 64 (2020). https://doi.org/10.1038/s41585-019-0276-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0276-1
